Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

HANDOK INC.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

Completed

Conditions: PNH

First Posted Date: 2022-04-20

Last Posted Date: 2025-01-28

Lead Sponsor: Handok Inc.

Target Recruit Count: 80

Registration Number: NCT05337683

Locations: 🇰🇷
Handok, Seoul, Korea, Republic of

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Phase 1

Terminated

Conditions: P2: Biliary Tract Cancer
P1b: Advanced Solid Tumors

Interventions: Drug: CTX-009 (ABL001)
Drug: Paclitaxel
Drug: Irinotecan

First Posted Date: 2020-07-30

Last Posted Date: 2025-01-27

Lead Sponsor: Handok Inc.

Target Recruit Count: 41

Registration Number: NCT04492033

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 1 locations

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Irbesartan/Amlodipine

First Posted Date: 2020-07-28

Last Posted Date: 2022-06-30

Lead Sponsor: Handok Inc.

Target Recruit Count: 440

Registration Number: NCT04488978

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Empagliflozin
Drug: Teneligliptin
Drug: Teneligliptin and Empagliflozin

First Posted Date: 2020-06-16

Last Posted Date: 2021-11-15

Lead Sponsor: Handok Inc.

Target Recruit Count: 32

Registration Number: NCT04431141

Locations: 🇰🇷
Clinical Pharmacology, Asan Medical Center, Seoul, Korea, Republic of

A Study to Assess Efficacy and Safety of the Ketoprofen vs Diclofenac

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Drug: Diclofenac Topical
Drug: Ketoprofen topical

First Posted Date: 2020-06-09

Last Posted Date: 2021-01-20

Lead Sponsor: Handok Inc.

Target Recruit Count: 236

Registration Number: NCT04421911

Locations: 🇷🇺
Maksimum Zdorovya, Kemerovo, Russian Federation
🇷🇺
City Clinical Hospital #1 n.a. Pirogova, Moscow, Russian Federation
🇷🇺
Rostov State Medical University, Rostov-on-Don, Russian Federation

and more 6 locations

Theracurmin vs Curcumin Bioavailability Study

Not Applicable

Completed

Conditions: Bioavailability

Interventions: Dietary Supplement: curmin

First Posted Date: 2019-07-23

Last Posted Date: 2019-12-06

Lead Sponsor: Handok Inc.

Target Recruit Count: 24

Registration Number: NCT04028739

Locations: 🇰🇷
Korea Kuro Hospital, Seoul, Korea, Republic of

A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Phase 1

Completed

Conditions: Solid Tumor, Adult
Phase 1

Interventions: Drug: NOV1601(CHC2014)

First Posted Date: 2019-07-10

Last Posted Date: 2021-09-16

Lead Sponsor: Handok Inc.

Target Recruit Count: 17

Registration Number: NCT04014257

Locations: 🇰🇷
National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 1 locations

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin

Completed

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2019-01-04

Last Posted Date: 2025-01-27

Lead Sponsor: Handok Inc.

Target Recruit Count: 2983

Registration Number: NCT03793023

Locations: 🇰🇷
Ajou University Hospital, Suwon, Gyeonggi, Korea, Republic of

A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: FDC(MP-513 10mg/Metformin XR 750mg)

First Posted Date: 2018-12-26

Last Posted Date: 2018-12-27

Lead Sponsor: Handok Inc.

Target Recruit Count: 30

Registration Number: NCT03787043

Locations: 🇰🇷
Clinical trials center of Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: FDC(MP-513 20mg/Metformin XR 1000mg)
Drug: MP-513 20mg
Drug: Metformin XR 1000mg

First Posted Date: 2018-12-26

Last Posted Date: 2018-12-27

Lead Sponsor: Handok Inc.

Target Recruit Count: 36

Registration Number: NCT03787017

Locations: 🇰🇷
Clinical trials center of Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy